BSE Live
Apr 02, 16:01Prev. Close
20.85
Open Price
19.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of Brawn Biotech (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | -5.68 | -4.15 | -3.04 | -5.25 | -1.55 | |
| Diluted EPS (Rs.) | -5.68 | -4.15 | -3.04 | -5.25 | -1.55 | |
| Cash EPS (Rs.) | -5.42 | -3.83 | -2.53 | -5.30 | -1.72 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 11.21 | 16.88 | 21.03 | 24.07 | 29.31 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 11.21 | 16.88 | 21.03 | 24.07 | 29.31 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 44.88 | 54.98 | 74.09 | 28.73 | 116.57 | |
| PBDIT/Share (Rs.) | -5.60 | -4.80 | -0.98 | -6.67 | -0.96 | |
| PBIT/Share (Rs.) | -5.98 | -5.13 | -1.34 | -6.85 | -1.08 | |
| PBT/Share (Rs.) | -5.99 | -5.15 | -1.37 | -7.06 | -1.20 | |
| Net Profit/Share (Rs.) | -5.80 | -4.16 | -2.89 | -5.48 | -1.84 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | -12.47 | -8.73 | -1.32 | -23.22 | -0.82 | |
| PBIT Margin (%) | -13.32 | -9.33 | -1.81 | -23.84 | -0.92 | |
| PBT Margin (%) | -13.35 | -9.36 | -1.85 | -24.56 | -1.02 | |
| Net Profit Margin (%) | -12.92 | -7.56 | -3.90 | -19.07 | -1.57 | |
| Return on Networth / Equity (%) | -51.75 | -24.61 | -13.75 | -22.77 | -6.26 | |
| Return on Capital Employed (%) | -16.07 | -19.06 | -6.21 | -27.53 | -3.60 | |
| Return on Assets (%) | -8.49 | -8.54 | -5.97 | -11.92 | -3.96 | |
| Total Debt/Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover Ratio (%) | 0.77 | 1.13 | 1.57 | 0.62 | 2.05 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.88 | 2.02 | 1.67 | 1.93 | 2.60 | |
| Quick Ratio (X) | 0.75 | 1.09 | 1.07 | 1.18 | 2.54 | |
| Inventory Turnover Ratio (X) | 1.63 | 0.00 | 0.00 | 0.00 | 5.09 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 4.68 | 5.60 | 4.53 | 4.98 | 6.23 | |
| EV/Net Operating Revenue (X) | 0.35 | 0.34 | 0.20 | 0.58 | 0.18 | |
| EV/EBITDA (X) | -2.78 | -3.89 | -15.39 | -2.49 | -21.54 | |
| MarketCap/Net Operating Revenue (X) | 0.36 | 0.36 | 0.22 | 0.60 | 0.19 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 1.45 | 1.18 | 0.79 | 0.72 | 0.75 | |
| Price/Net Operating Revenue | 0.36 | 0.36 | 0.22 | 0.60 | 0.19 | |
| Earnings Yield | -0.36 | -0.21 | -0.17 | -0.32 | -0.08 |
24.11.2025
Brawn Pharma Standalone September 2025 Net Sales at Rs 4.89 crore, up 48.36% Y-o-Y
28.05.2025
Brawn Pharma Standalone March 2025 Net Sales at Rs 2.26 crore, down 34.45% Y-o-Y
17.02.2025
Brawn Pharma Standalone December 2024 Net Sales at Rs 3.84 crore, up 35.25% Y-o-Y
25.11.2024
Brawn Pharma Standalone September 2024 Net Sales at Rs 3.30 crore, up 12.95% Y-o-Y
24.11.2025
Brawn Pharma Standalone September 2025 Net Sales at Rs 4.89 crore, up 48.36% Y-o-Y
28.05.2025
Brawn Pharma Standalone March 2025 Net Sales at Rs 2.26 crore, down 34.45% Y-o-Y
17.02.2025
Brawn Pharma Standalone December 2024 Net Sales at Rs 3.84 crore, up 35.25% Y-o-Y
25.11.2024
Brawn Pharma Standalone September 2024 Net Sales at Rs 3.30 crore, up 12.95% Y-o-Y
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
02.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth